NVAX (novavax.com) Enterprise Value-to-Revenue Ratio

Public company logo of Novavax Inc (NVAX)

Complex cold chain logistics increase delivery costs for Novavax, Inc. (NVAX), creating volatility as reflected in the EV/Sales multiple chart. The latest value is recorded as 2299.94. Stability is provided by a strategy to transition toward commercial protein vaccines supported by a global alliance. Simultaneously, Novavax, Inc. (NVAX) is optimizing costs by switching contract manufacturers and implementing a seamless outsourcing management model.

NVAX Novavax Pharma Company Value to Revenue (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Novavax, Inc. (NVAX)

- price and consensus price forecast:
- business market valuation indicators:
Fundamental valuation:Novavax, Inc. NVAX
Mass-produced product of Novavax Pharma

Novavax, Inc. (NVAX) is transforming its business model, shifting from COVID-19 products toward combination vaccines and licensing. By analyzing the enterprise value-to-annual revenue multiple, an investor assesses the market value of the business excluding debt load. This chart reflects the efficiency of operational growth relative to capitalization. A decline in this metric confirms the fundamental strengthening of the company's position, allowing analysts to strip away share price volatility when valuing real assets.